KRAS and colorectal carcinoma: Importantly, elevated mutant KRAS expression showed an inverse correlation with intratumoral CD8+ T cell density.[38] Stratification of KRAS mutation subtypes in CRC showed no significant differences in the intratumoral CD8+ T cell density across different KRAS mutation types (e.g., KRAS G12D, G12V, G13D, and others).[38b] In PDAC, variations in the spatial distribution of CD8+ T cells may arise due to specific KRAS mutations such as G12D and G12R.